Study of combination of vildagliptin with metformin and glimepiride with metformin in type2 diabetic patients

To compare the effect of vildagliptin with metformin versus glimepiride with metformin on inflammatory markers and glycaemic control in type2 diabetes mellitus patients - VilMeGliMeD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/01/039090

Enrollment

Registered

2022-01-03

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Vildagliptin with Metformin : Tablet Vildagliptin (50 to 100mg/per day) with tablet Metformin ( 500 to 2000mg/per day) for12 weeks Initially, Tablet vildagliptin 50 mg with tablet metf

Eligibility

Inclusion criteria

Inclusion criteria: Patients above 18 years old age, of either sex with type 2 diabetes mellitus Newly diagnosed type 2 diabetes mellitus patient with HBA1C >8%

Exclusion criteria

Exclusion criteria: Other types of diabetes patients with inflammatory disease (inflammatory bowel disease, lupus, arthritis), hepatic or renal impairment, malignancy, thrombosis and conditions other than type 2 diabetes mellitus Who are on steroids, anti-inflammatory and immunomodulatory drugs

Design outcomes

Primary

Measure	Time frame
to assess the effect of combination therapy on the glycemic level and inflammatory markersTimepoint: FBS/RBS at 0,2,4,8,10,12 weeks while HBA1C and inflammatory markers(IL6, hCRP and ESR) at 0 and 12 weeks, Other test LFT and RFT 0,2,4,8,10,12 weeks	—

Secondary

Measure	Time frame
Assess the adverse eventsTimepoint: during and after study period	—

Countries

India

Contacts

Public ContactDr Rajkumar

Guru Gobind Singh medical college and hospital

anurajkumar76@gmail.com9646599057

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026